Preclinical drug development services provided by Mavens Group include IND and NDA enabling studies, impurity qualifying and bridging studies for regulatory submissions, and 505 (B2) strategies.
Our knowledge of DMPK, genetic toxicology, mammalian toxicology, formulation, and bioanalysis, as well as technique development and validation, is extensive.
Over the years, our diverse scientific team, led by subject specialists, has assisted our clients in submitting projects successfully and on schedule.
From our state-of-the-art Chemistry laboratory, we additionally support Discovery/Medicinal Chemistry, Custom Synthesis, Process R&D, and scale-up.
Recent Comments